SWM
CYTK icon

SHP Wealth Management’s Cytokinetics CYTK Stock Holding History

SHP Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$725 Buy
+11
New +$699 ﹤0.01% 1547

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SHP Wealth Management's CYTK Position: Q1 2026 in Review

SHP Wealth Management opened a new position in Cytokinetics (CYTK) in Q1 2026: 11 shares worth $725. The stake represents ﹤0.01% of the portfolio and ranks #1547 among its holdings.

439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • SHP Wealth Management held 11 shares of Cytokinetics worth $725 as of Q1 2026.
  • Cytokinetics was a new SHP Wealth Management position in Q1 2026.
  • Cytokinetics made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1547 holding.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.